Pacific Biosciences of California Inc (PACB): Insights At A Glance

Pacific Biosciences of California Inc (PACB) concluded trading on Wednesday at a closing price of $1.27, with 6.26 million shares of worth about $7.95 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -27.01% during that period and on March 26, 2025 the price saw a loss of about -3.05%. Currently the company’s common shares owned by public are about 294.42M shares, out of which, 264.86M shares are available for trading.

Stock saw a price change of 1.60% in past 5 days and over the past one month there was a price change of -18.59%. Year-to-date (YTD), PACB shares are showing a performance of -30.60% which decreased to -65.49% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.16 but also hit the highest price of $3.89 during that period. The average intraday trading volume for Pacific Biosciences of California Inc shares is 11.14 million. The stock is currently trading -2.78% below its 20-day simple moving average (SMA20), while that difference is down -14.74% for SMA50 and it goes to -25.97% lower than SMA200.

Pacific Biosciences of California Inc (NASDAQ: PACB) currently have 294.42M outstanding shares and institutions hold larger chunk of about 77.62% of that.

The stock has a current market capitalization of $378.28M and its 3Y-monthly beta is at 2.01. It has posted earnings per share of -$1.62 in the same period. It has Quick Ratio of 6.59 while making debt-to-equity ratio of 1.33. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PACB, volatility over the week remained 5.19% while standing at 8.03% over the month.

Stock’s fiscal year EPS is expected to rise by 33.69% while it is estimated to increase by 17.06% in next year. EPS is likely to grow at an annualized rate of 24.02% for next 5-years, compared to annual growth of -23.55% made by the stock over the past 5-years.

Coverage by Jefferies stated Pacific Biosciences of California Inc (PACB) stock as a Buy in their note to investors on June 03, 2024, suggesting a price target of $4 for the stock. On April 22, 2024, JP Morgan Downgrade their recommendations, while on April 18, 2024, Goldman Downgrade their ratings for the stock with a price target of $2.50. Stock get an Overweight rating from Stephens on December 14, 2023.

Most Popular

Related Posts